Elanco has announced the results of a challenge study which the company says demonstrates the ability of Duvaxyn IE-T Plus equine influenza vaccine to cross protect against A/equi-2/Richmond/1/07 (H3N8) two weeks after a two dose primary course1.
The study…
Elanco Animal Health has highlighted the results of a new study1 which concludes that Duvaxyn IE-T Plus stimulates a highter protective antibody response than four other equine influenza vaccines commercially available in Ireland.
The trial compared the…